Twist Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Twist Bioscience Corporation on March 28, 2023, covering events occurring on March 23, 2023. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol "TWST."
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report is limited to corporate governance and personnel changes.
Material Changes
The primary material change reported is the resignation of Kevin Yankton, the Company's Chief Accounting Officer. His resignation is effective May 19, 2023, to pursue other interests. The Company explicitly states that the departure is not the result of any disagreement regarding financial reporting, operations, policies, or practices.
Management Commentary and Contingencies
Management has initiated a search for Mr. Yankton's successor. In the interim, the Company has engaged an expert financial consultant who will report to James Thorburn. Mr. Thorburn, currently the Chief Financial Officer, will serve as the principal accounting officer until a permanent successor is appointed.
Key Facts for Investor Verification
- Kevin Yankton, Chief Accounting Officer, is resigning effective May 19, 2023.
- The resignation is voluntary and unrelated to any disputes over financial reporting or operations.
- James Thorburn (CFO) will assume the role of principal accounting officer temporarily.
- An external expert financial consultant has been engaged to assist during the transition.
- No financial performance data is disclosed in this specific filing.